BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24390224)

  • 41. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
    Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
    Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
    Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
    Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
    Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
    Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
    Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
    Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients.
    Wang H; Ye J; Qian H; Zhou R; Jiang J; Ye L
    Genet Test Mol Biomarkers; 2015 Mar; 19(3):162-6. PubMed ID: 25615570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53 alterations in uterine leiomyosarcomas versus leiomyomas.
    de Vos S; Wilczynski SP; Fleischhacker M; Koeffler P
    Gynecol Oncol; 1994 Aug; 54(2):205-8. PubMed ID: 8063247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
    Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
    Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential Expression of MED12-Associated Coding RNA Transcripts in Uterine Leiomyomas.
    Chuang TD; Gao J; Quintanilla D; McSwiggin H; Boos D; Yan W; Khorram O
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
    Packenham JP; du Manoir S; Schrock E; Risinger JI; Dixon D; Denz DN; Evans JA; Berchuck A; Barrett JC; Devereux TR; Ried T
    Mol Carcinog; 1997 Aug; 19(4):273-9. PubMed ID: 9290705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fumarase-deficient Uterine Leiomyomas: An Immunohistochemical, Molecular Genetic, and Clinicopathologic Study of 86 Cases.
    Miettinen M; Felisiak-Golabek A; Wasag B; Chmara M; Wang Z; Butzow R; Lasota J
    Am J Surg Pathol; 2016 Dec; 40(12):1661-1669. PubMed ID: 27454940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma.
    Peng Y; Laser J; Shi G; Mittal K; Melamed J; Lee P; Wei JJ
    Mol Cancer Res; 2008 Apr; 6(4):663-73. PubMed ID: 18403645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
    Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
    Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas.
    McGuire MM; Yatsenko A; Hoffner L; Jones M; Surti U; Rajkovic A
    PLoS One; 2012; 7(3):e33251. PubMed ID: 22428002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.
    Mäkinen N; Heinonen HR; Moore S; Tomlinson IP; van der Spuy ZM; Aaltonen LA
    Oncotarget; 2011 Dec; 2(12):966-9. PubMed ID: 22182697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases.
    Dundr P; Gregová M; Hojný J; Krkavcová E; Michálková R; Němejcová K; Bártů M; Hájková N; Laco J; Mára M; Richtárová A; Zima T; Stružinská I
    Virchows Arch; 2022 Feb; 480(2):281-291. PubMed ID: 34626221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell cultures in uterine leiomyomas: rapid disappearance of cells carrying MED12 mutations.
    Nadine Markowski D; Tadayyon M; Bartnitzke S; Belge G; Maria Helmke B; Bullerdiek J
    Genes Chromosomes Cancer; 2014 Apr; 53(4):317-23. PubMed ID: 24446130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
    Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
    Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
    Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
    JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.